Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
Holdings in Q2 2021
Holdings as of Jun 30, 2021, filed Oct 14, 2021. Long positions only; changes compare share counts with Q1 2021.
- Positions
- 29
- −2 vs. Q1 2021
- Portfolio value
- $287.0M
- +$36.0M (+14.3%) vs. Q1 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| BCLS Acquisition CorpG0904B105 | COM CL A | 250,000 | $2.63M | 0.9% | 00.0% | Unchanged | – |
| SPRYARS Pharmaceuticals, Inc. | COM | 97,143 | $3.00M | 1.0% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 186,405 | $3.41M | 1.2% | +624+0.3% | Added | History |
| Catabasis Pharmaceuticals IN14875P206 | COM NEW | 1,617,000 | $3.41M | 1.2% | +1,617,000 | New | – |
| MCRBSeres Therapeutics, Inc. | COM | 145,453 | $3.47M | 1.2% | +4,150+2.9% | Added | History |
| IVAInventiva S.A. | ADS | 262,658 | $3.58M | 1.2% | 00.0% | Unchanged | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 125,000 | $4.27M | 1.5% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 226,671 | $5.43M | 1.9% | +12,204+5.7% | Added | History |
| MRSNMersana Therapeutics, Inc. | COM | 429,228 | $5.83M | 2.0% | 00.0% | Unchanged | History |
| XENEXenon Pharmaceuticals Inc. | COM | 326,336 | $6.08M | 2.1% | +24,944+8.3% | Added | History |
| DYNDyne Therapeutics, Inc. | COM | 305,125 | $6.42M | 2.2% | −124,987−29.1% | Reduced | History |
| MREOMereo BioPharma Group plc | SPON ADS | 2,059,729 | $6.53M | 2.3% | +10,972+0.5% | Added | History |
| GNCAGenocea Biosciences, Inc. | COM NEW | 2,929,447 | $6.86M | 2.4% | +57,823+2.0% | Added | History |
| KRONKronos Bio, Inc. | COM | 298,839 | $7.16M | 2.5% | 00.0% | Unchanged | History |
| EPIXESSA Pharma Inc. | COM NEW | 281,911 | $8.05M | 2.8% | +105,090+59.4% | Added | History |
| PTGXProtagonist Therapeutics, Inc | COM | 210,600 | $9.45M | 3.3% | −139,000−39.8% | Reduced | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 3,331,315 | $10.5M | 3.7% | −398,379−10.7% | Reduced | History |
| MGNXMacrogenics Inc | COM | 393,850 | $10.6M | 3.7% | +347,220+744.6% | Added | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 323,437 | $10.8M | 3.8% | −46,514−12.6% | Reduced | History |
| ISEEIVERIC bio, Inc. | COM | 1,748,241 | $11.0M | 3.8% | +19,200+1.1% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 1,367,582 | $11.1M | 3.9% | +98,387+7.8% | Added | History |
| KURAKura Oncology, Inc. | COM | 621,493 | $13.0M | 4.5% | +99,938+19.2% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 704,317 | $13.9M | 4.9% | +704,317 | New | History |
| CNSTConstellation Pharmaceuticals Inc | COM | 440,869 | $14.9M | 5.2% | +72,421+19.7% | Added | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 3,529,465 | $15.4M | 5.4% | +545,952+18.3% | Added | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 481,094 | $18.2M | 6.3% | 00.0% | Unchanged | History |
| CELCCelcuity Inc. | COM | 870,967 | $20.9M | 7.3% | +870,967 | New | History |
| STSASatsuma Pharmaceuticals, Inc. | COM | 3,096,729 | $21.8M | 7.6% | +665,024+27.3% | Added | History |
| ACRSAclaris Therapeutics, Inc. | COM | 1,668,987 | $29.3M | 10.2% | +640,903+62.3% | Added | History |
Sold out since Q1 2021 (5)
Positions held at the end of Q1 2021 that are gone from this filing.
| Security | Class | Shares in Q1 2021 | Value in Q1 2021 | % of portfolio in Q1 2021 | History |
|---|---|---|---|---|---|
| Five Prime Therapeutics Inc33830X104 | COM | 361,344 | $13.6M | 5.4% | – |
| Trillium Therapeutics Inc.89620X506 | COM NEW | 795,868 | $8.55M | 3.4% | – |
| RLMDRelmada Therapeutics, Inc. | COM | 161,565 | $5.69M | 2.3% | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 236,500 | $5.29M | 2.1% | History |
| SNCEScience 37 Holdings, Inc. | COM | 100,000 | $1.01M | 0.4% | History |